HHS Names a Healthcare Advisory Committee, Senate Democrats Demand the NBPP Be Pulled, and the CRUSH Comment File Closes

The last full week of March produced one of the busiest regulatory news cycles of the year, anchored by Friday's announcement that Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz had picked the 18 members of a new federal Healthcare Advisory Committee charged with rewriting how HHS thinks about Medicare, Medicaid, CHIP and the Marketplace. The same Friday morning, March 27, the Trump administration also published the year's most consequential update to the agency's price-transparency posture, telegraphing a proposed rule that would force health plans and hospitals to standardize, simplify and shorten the way they disclose negotiated rates. Layered on top of those two announcements were a Senate Democratic letter demanding the agency withdraw its proposed 2027 Notice of Benefit and Payment Parameters, the closing of the comment file on the CMS Comprehensive Regulations to Uncover Suspicious Healthcare initiative, and the publication of Highmark Health's full-year 2025 financials four business days before the Blue Cross and Blue Shield of Kansas City affiliation closes. By Friday evening every major payer trade association had statements out, and the agency's regulatory pipeline for the second quarter had effectively rewritten itself in a single week.

Eighteen names, four hundred applicants, and a non-binding mandate

The advisory committee announcement, posted to the CMS newsroom mid-morning Friday and amplified on a joint HHS-CMS YouTube broadcast, marked the operational debut of a body that has been in the works since Kennedy's confirmation hearings last year. According to the agency's release, the secretary personally reviewed more than 400 candidates before settling on a roster designed, in the agency's framing, to "drive Kennedy's Make America Healthy Agenda by developing policy on tackling chronic diseases, reducing administrative burden, and enhancing care for vulnerable populations." The 18-member panel is heavy on private-sector executives — STAT's reporting Friday afternoon counted leaders from value-based primary care, mental health and digital health alongside a venture capitalist who had previously worked with Kennedy's son and, in the description that drew the most immediate attention from health policy wonks, a motivational coach. The committee will provide non-binding recommendations, but the breadth of its remit — Medicare, Medicaid, CHIP and the Health Insurance Marketplace, plus an explicit mandate to advise on "how care is financed and delivered" — gives it a wider lane than most federal advisory committees enjoy.

For carriers and benefit advisors trying to read the regulatory tea leaves, the committee's composition matters less than the signal it sends about where the agency wants to spend its political capital in the second half of 2026. The early reaction from Hill Democrats was skeptical; Senate Finance staff told reporters Friday that the committee's heavy private-sector tilt and the absence of consumer advocacy or labor representatives suggested a body designed to ratify existing administration priorities rather than introduce new ones. Republican leadership was more receptive, with Senate HELP Chair Bill Cassidy welcoming the panel as "a long-overdue venue for moving past Washington's bureaucratic instincts and back toward outcomes-based reform." Either way, the committee's first scheduled meeting falls in the second quarter, and its members will inherit a regulatory pipeline that includes the still-pending CY 2027 Medicare Advantage rate notice (final due April 6), the 2027 NBPP final rule, and the second wave of CMS Innovation Center model launches that begins in July with the ACCESS chronic-care payment pilot.

A price-transparency proposal designed to force the data into use

The same Friday morning brought a CMS press release headlined "Trump Administration Proposes Significant Updates to Disclosure Requirements to Make Health Care Prices Clear, Accurate, and Actionable for Americans," a long title that captures the policy aim succinctly. The proposed rule, which builds on the December 19, 2025 transparency-in-coverage update and the November 2025 hospital price-transparency final rule, takes aim at the core complaint that compliance officers and benefits consultants have lodged against the existing transparency regime since 2022: the data exists, but it is unusable. CMS proposes to require plans and issuers to prepare a single in-network rate file per provider network rather than per plan, to deliver identical cost-share information whether the consumer queries by phone, online or in print, and to expand the volume of out-of-network pricing data through a lower claims-volume threshold (eleven claims rather than twenty) and a longer reporting window (six months rather than ninety days). The Friday release framed the changes as "the next step toward a market in which patients, employers and providers can actually shop on price."

The hospital side of the rule, finalized last November but with enforcement of the central machine-readable-file revisions delayed until April 1, 2026, will start biting on Wednesday — three days after this writing. From April 1 onward, hospitals must publish actual median allowed amounts (no longer "estimated") plus 10th and 90th percentile allowed amounts in their machine-readable files, calculated from electronic 835 remittance advice data or an equivalent source. The combination of the April 1 hospital enforcement trigger and Friday's payer-side proposal creates the most consequential transparency moment since the No Surprises Act took effect, and it lands at the same time CMS is asking employers and brokers, through the December 19 Transparency in Coverage proposal, to submit comments on whether the existing in-network rate files should be reorganized by network rather than plan. Comment periods on the new payer proposal run for sixty days from publication in the Federal Register, putting the next deadline squarely in late May.

Senate Democrats line up against the 2027 NBPP

Thursday, March 26, brought a sharply worded letter from Senators Tammy Baldwin (D-WI), Chuck Schumer (D-NY) and Ron Wyden (D-OR), joined by 14 Democratic colleagues, demanding that Administrator Oz withdraw the 2027 Notice of Benefit and Payment Parameters whose comment period closed on March 13. The letter, posted on Senator Baldwin's website Thursday afternoon, argued that the agency's own actuarial analysis predicts the rule would push two million Americans off ACA coverage and that the proposed regulatory framework — particularly the network-adequacy rollback and the addition of non-network plan designs — would "increase deductibles, cover fewer services, and kick providers out of network." The senators framed the letter as a direct response to the affordability crisis documented by the KFF poll released March 19, the same survey that found 80% of returning enrollees reporting higher 2026 costs and 9% of November 2025 respondents already dropping coverage.

The letter was the third major piece of organized stakeholder pushback against the 2027 NBPP since the comment period closed: AHIP, the Blue Cross Blue Shield Association, the Federation of American Hospitals, the AMA and Families USA had all submitted formal comments arguing against various elements of the rule, and a coalition of state insurance regulators had filed a joint comment letter on March 12 expressing concern about the network-adequacy provisions. The Senate letter raised the political stakes by tying the rulemaking to the broader Democratic message frame that Wyden's "Health Coverage That Works for Everyone" framework had introduced March 19. The agency has not committed to a final rule timeline; under recent practice, NBPP final rules typically publish in late April or early May, but the volume and tone of the comments — and now the Senate letter — make a slipped timeline plausible.

CRUSH closes its file as Highmark posts a $175 million loss

Monday, March 30, the day this post publishes, is also the day the comment file on the CMS Comprehensive Regulations to Uncover Suspicious Healthcare RFI closes. The CRUSH RFI, published February 27 in the Federal Register and covering 13 distinct topics from DMEPOS supplier oversight to AI-assisted coding to Medicare Advantage prior-authorization practices, has drawn an unusually broad range of submissions in the two weeks leading up to the deadline. The American Hospital Association posted its 31-page response Monday morning, recommending that CMS focus its enforcement attention on Medicare Advantage organizations whose "complex prior authorization requirements and opaque coverage rules" the AHA argued were themselves a vector for waste. The Alliance of Specialty Medicine submitted comments specifically opposing additional prior-authorization burden under the WISeR utilization-management model, and individual state hospital associations, the Pennsylvania Homecare Association, the Association for Molecular Pathology and the National State Auditors Association all filed separately. The agency is expected to use the comment file to scope a proposed rule later in the year, with industry observers anticipating the most concrete near-term action will be on DMEPOS provider enrollment and on AI-coding oversight rather than on Medicare Advantage prior-authorization itself.

The CRUSH proceedings landed in the same week that Highmark Health, four business days before its Blue KC affiliation closes Tuesday, March 31, posted full-year 2025 financials that put a number on the financial pressure non-profit Blues plans have absorbed during the post-pandemic claims-trend period. In a Tuesday, March 24 release, Highmark reported $32.4 billion in revenue (an 11% year-over-year increase representing more than $3 billion in top-line growth), but a $674 million operating loss and a $175 million net loss for the twelve months ended December 31, 2025. The insurance division alone posted a $609 million operating loss on $24.8 billion in operating revenue, while the provider system, Allegheny Health Network, posted $5.7 billion in revenue and $90 million in operating income — a $237 million year-over-year improvement that the company highlighted as evidence of the value of its integrated payer-provider model. Highmark Health closed the year with $11.8 billion in cash and investments and net assets of $9.8 billion. The release also confirmed that the affiliation with Blue KC, which adds roughly one million members, $3 billion in annual revenue and 1,200 employees to the Highmark system and vaults the combined organization into third place among Blues affiliates nationwide, would close on March 31 as planned.

The week's three threads — the regulatory reset signaled by the advisory committee and price-transparency proposal, the political pressure on the NBPP, and the financial reality reflected in Highmark's loss and the CRUSH comment file — share an underlying logic. The Trump administration is using its regulatory capacity to pursue what its principals describe as system reform: a smaller, less heavily subsidized ACA marketplace; a Medicare Advantage program subject to tighter risk-adjustment and prior-authorization scrutiny under CRUSH; a price-transparency regime designed to force buy-side use of negotiated-rate data. Carriers and large employers are responding by accelerating consolidation (the Highmark/Blue KC closing on Tuesday is the most visible example, but Independence/AmeriHealth Caritas and Florida Blue/GuideWell are running on similar tracks), by adjusting risk pools where the marketplace economics no longer make sense (Centene's ACA membership has fallen from 5.6 million to 3.6 million year over year), and by absorbing operating losses where pricing has not caught up with claims trend.

For employer plan sponsors, brokers and individual enrollees, three near-term dates frame what comes next:

• April 1: Hospital price-transparency machine-readable file revisions take effect with median and 10th/90th percentile allowed amounts replacing prior estimates
• April 6: CY 2027 Medicare Advantage final rate notice publishes after a CMS lobbying push that has trade associations expecting an upward revision from the proposed +0.09% baseline
• Late May: Comments due on the new Transparency in Coverage proposal, with a final rule expected before the end of 2026

What the Healthcare Advisory Committee will recommend, when the 2027 NBPP final rule actually drops, and how the CRUSH comment record translates into a proposed rule are open questions that will shape the rest of the year. What is not in question is that the regulatory cadence has accelerated: between the February 27 CRUSH RFI, the December 19 transparency-in-coverage proposal, the March 13 NBPP comment close, the Friday advisory committee announcement, the Friday price-transparency proposal and the Tuesday Highmark/Blue KC close, the agency and its regulated parties have generated more rule-shaping activity in twelve weeks than in any comparable stretch since 2022. The April 6 rate notice will tell carriers how much of the cost trend the federal government plans to absorb in 2027. Everything else in the second-quarter regulatory calendar will tell employers and brokers how the rules they have to live by are going to change.

What the week did to the regulatory calendar

The clearest signal from the week is that Q2 2026 will be a more crowded regulatory quarter than Q1. The Healthcare Advisory Committee has not yet scheduled its first meeting, but the agency's procurement timeline and the panel's stated focus areas — chronic disease, administrative burden, vulnerable populations — line up with the policy areas where CMS has the most discretion to issue sub-regulatory guidance: Medicare Innovation Center model design, Medicaid waiver approvals, prescription-drug coverage interpretations and the marketplace standards that the NBPP final rule will codify. The price-transparency proposal, the CRUSH comment record and the NBPP final rule are interlocking pieces of the same project: a federal effort to reset the rules of the road in commercial, Medicare Advantage and ACA markets simultaneously. Whether the Healthcare Advisory Committee turns out to be a meaningful policy venue or a ceremonial one, the regulatory pipeline it inherits is dense enough that the next four months will define the remainder of 2026 for every carrier, every employer plan sponsor and every broker working in commercial and government markets.

For the brokers and benefits consultants whose calendars revolve around the regulatory cycle, the week was a reminder that the post-CMS-CRUSH, post-NBPP, post-transparency landscape is not converging on any single answer. It is converging on a much higher tempo of change — and on a federal agency that, in the description Administrator Oz offered Friday morning when he introduced the new committee members, is "moving past the bureaucratic instincts that have failed American patients and toward a system that finally rewards results."